Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of IGV-001, in ndGBM individuals.

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his ...

Ryght AI has partnered with Cancer Research South Australia (CRSA) to advance cancer clinical trials and expand patient ...

Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...